 IRVINE, CA ACCESSWIRE April 5, 2021 Hancock Jaffe Laboratories, Inc. NASDAQ:HJLI, a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration FDA has approved the companys Investigational Device Exemption IDE application to begin the U.S. pivotal trial for the VenoValve. The VenoValve is an implantable valve designed to restore proper directional blood flow for patients with Chronic Venous Insufficiency CVI of the deep veins of the leg, a condition that afflicts approximately 2.4 million patients in the U.S. and for which there are currently no effective treatments. 